Application of oleanolic acid in preparation of medicine for treating and preventing diseases caused by porcine pseudorabies virus

By using oleanolic acid to prepare drug formulations in various dosage forms, the problem of treating and preventing pseudorabies virus disease has been solved, achieving effective inhibition and treatment of pseudorabies virus, especially in the prevention and control of pigs, filling a gap in existing technologies.

CN118976030APending Publication Date: 2024-11-19HEILONGJIANG BAYI AGRICULTURAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410474076.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-04-19
Publication Date
2024-11-19

Smart Images

  • Figure CN118976030A_ABST
    Figure CN118976030A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of animal husbandry, and discloses application of oleanolic acid in preparation of a medicine for treating and preventing diseases caused by porcine pseudorabies virus. The research on the inhibition effect of the oleanolic acid on the pseudorabies virus in a PK-15 cell discovers that the oleanolic acid can be used as a drug for preventing and treating pseudorabies virus infection, and has an application value on the treatment of the pseudorabies virus infection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of animal husbandry and relates to application of oleanolic acid in preparing medicines for treating and preventing diseases caused by pseudorabies virus in pigs. Background Art

[0002] Pseudorabies virus (PRV) belongs to the α-herpesvirus subfamily of the Herpesviridae family. The virus particles are oval or round, and the mature virus particles are about 150-180nm in diameter. They have an envelope and the genome is a linear double-stranded DNA molecule of about 150kb. Pseudorabies is an acute infectious disease caused by PRV infection, which is shared by a variety of livestock and mammals. Pigs are the natural host and reservoir of PRV. During the breeding process, PRV infection can cause abortion and stillbirth in pregnant sows, infertility in boars, neurological disorders and rapid death in piglets, respiratory diseases in fattening pigs, and slow growth. Not only has it caused huge economic losses to the pig farming industry, but there have also been many cases of human infection. According to relevant reports, from 2017 to date, there have been 23 cases of PRV infection confirmed by mNGS in China, of which 4 died with a mortality rate of 17.4%, 2 were in a vegetative state, 2 were on ventilators to maintain minimum vital signs, 3 were in a coma, 6 were blind, and 6 could only take care of themselves. The above shows that pseudorabies in pigs can be transmitted to humans, and most patients have poor recovery after infection, and the survivors are left with severe disabilities and impaired living ability.

[0003] In the related technologies, there is no specific medicine for pseudorabies virus, and it can only be prevented for pigs through vaccines. Once pseudorabies virus begins to spread in pig farms, it will cause significant economic damage to the pig farming industry and will also infect humans. However, the existing vaccines only have a preventive effect on pig infection, but not on humans, so it is urgent and needed to develop effective drugs for the disease. PRV has become an important threat to public health and healthy breeding. At present, there are no effective drugs and treatments for pseudorabies in pigs. Vaccine prevention and pig purification are the main methods for preventing and controlling pseudorabies in pigs. With the development of antiviral research, it has become possible to screen and develop drugs against pseudorabies virus. Screening drugs for the treatment of pseudorabies in pigs has become a technical problem that needs to be solved in the field of veterinary prevention and control drug technology.

[0004] Oleanolic acid is widely used in the treatment of liver diseases. It is a pentacyclic triterpenoid natural product found in various plants, especially olives, where it can reach a high concentration in olive peels. Oleanolic acid has a variety of biological activities, including anti-inflammatory, anti-diabetic, antioxidant, cardioprotective, antibacterial and antiparasitic activities, so oleanolic acid and its derivatives are worthy of further study: for example, when the 3-hydroxyl group is replaced by phthaloyloxy, the derivative can show an inhibitory activity below 5 μM, among which the compound with C28 carboxyl coupled to two amino acids 6AHA-VAL shows the best inhibitory effect. The oleanolic acid derivative has good HIV-1 protease inhibitory activity; for example, the oleanolic acid derivative with the introduction of a carbonyl group at the C3 position, that is, oleanolic acid, is a hepatitis B virus deoxyribonucleic acid HBV-DNA inhibitor, which can not only inhibit the secretion of HBsAg in HepG 2.2.15 cells, but also reduce the secretion of HbeAg, and has the effect of inhibiting the hepatitis B virus surface antigen HBsAg. Summary of the invention

[0005] The technical problem to be solved by the present invention is how to prepare a drug for preventing and / or treating a disease caused by pseudorabies virus or pseudorabies virus infection, and / or how to prepare a pseudorabies virus inhibitor.

[0006] In order to solve the above technical problems, the first purpose is to provide the use of oleanolic acid in the preparation of a drug for preventing and / or treating a disease caused by pseudorabies virus or a drug for pseudorabies virus infection; the structural formula of the oleanolic acid is:

[0007]

[0008] In the above application, the disease caused by the pseudorabies virus may be an infectious disease caused by the pseudorabies virus or its complications. For example, pseudorabies in pigs is a disease caused by pseudorabies virus and occurs in pigs. The sick piglets suddenly become ill on the second day after birth, showing high fever, depression, lethargy, vomiting, diarrhea, screaming, ataxia, circling, and blind paddling of the limbs after falling to the ground; some sick pigs have symptoms such as coughing, runny nose, sneezing, etc., and some sick pigs show symptoms of central nervous system disorders, such as rigidity, paroxysmal spasms, hind limb movement disorders, etc., and the mortality rate is often lower than that of fattening pigs. Fattening pigs are less likely to show neurological symptoms when infected, and they present transient cold-like symptoms, accompanied by encephalomyelitis.

[0009] In the above application, the drug is administered to a mammal, specifically a non-human mammal, and more specifically a pig.

[0010] The second object of the present invention is to provide the use of oleanolic acid in the preparation of pseudorabies virus inhibitors.

[0011] In the above application, the drug is administered to a mammal, specifically a non-human mammal, and more specifically a pig.

[0012] The third object of the present invention is to provide the use of oleanolic acid in the preparation of a drug for inhibiting the proliferation of pseudorabies virus.

[0013] In the above application, the drug is administered to a mammal, specifically a non-human mammal, and more specifically a pig.

[0014] The fourth object of the present invention is to provide the use of oleanolic acid in the preparation of a drug for inhibiting the cytopathic effect of pseudorabies virus.

[0015] In the above application, the cells are mammalian cells.

[0016] In the above application, the mammalian cells are pig cells.

[0017] The present invention also provides a pseudorabies virus inhibitor, wherein the active ingredient of the pseudorabies virus inhibitor contains oleanolic acid.

[0018] The pseudorabies virus inhibitor may be only oleanolic acid, or may also contain a carrier or excipient. The carrier material includes, but is not limited to, a water-soluble carrier material (such as polyethylene glycol, polyvinyl pyrrolidone, organic acid, etc.), a poorly soluble carrier material (such as ethyl cellulose, cholesterol stearate, etc.), and an enteric carrier material (such as cellulose acetate phthalate and carboxymethyl ethyl cellulose, etc.). Specifically, a water-soluble carrier material. These materials can be used to make a variety of dosage forms, including but not limited to tablets, capsules, dripping pills, aerosols, pills, powders, solutions, suspensions, emulsions, granules, liposomes, transdermal agents, buccal tablets, suppositories, freeze-dried powder injections, etc. It can be a common preparation, a sustained-release preparation, a controlled-release preparation, and various microparticle delivery systems. In order to make a unit dosage form into a tablet, various carriers known in the art can be widely used. Examples of carriers include diluents and absorbents, such as starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, urea, calcium carbonate, kaolin, microcrystalline cellulose, aluminum silicate, etc.; wetting agents and binders, such as water, glycerol, polyethylene glycol, ethanol, propanol, starch paste, dextrin, syrup, honey, glucose solution, acacia paste, gelatin paste, sodium carboxymethylcellulose, shellac, methylcellulose, potassium phosphate, polyvinyl pyrrolidone, etc.; disintegrants. , such as dry starch, alginate, agar powder, brown algae starch, sodium bicarbonate and citric acid, calcium carbonate, polyoxyethylene, sorbitan fatty acid esters, sodium lauryl sulfate, methyl cellulose, ethyl cellulose, etc.; disintegration inhibitors, such as sucrose, tristearate, cocoa butter, hydrogenated oil, etc.; absorption promoters, such as quaternary ammonium salts, sodium lauryl sulfate, etc.; lubricants, such as talc, silicon dioxide, corn starch, stearate, boric acid, liquid paraffin, polyethylene glycol, etc. The tablets can also be further made into coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or double-layer tablets and multi-layer tablets. In order to make the unit dosage form into a pill, various carriers known in the art can be widely used. Examples of carriers include diluents and absorbents, such as glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, polyvinyl pyrrolidone, Gelucire, kaolin, talc, etc.; binders such as gum arabic, tragacanth, gelatin, ethanol, honey, liquid sugar, rice paste or flour paste, etc.; disintegrants such as agar powder, dry starch, alginate, sodium dodecyl sulfate, methyl cellulose, ethyl cellulose, etc. In order to prepare the unit dosage form into a suppository, various carriers known in the art can be widely used. Examples of carriers include, for example, polyethylene glycol, lecithin, cocoa butter, higher alcohols, esters of higher alcohols, gelatin, semi-synthetic glycerides, etc. In order to prepare the unit dosage form into an injectable preparation, such as a solution, emulsion, freeze-dried powder injection and suspension, all diluents commonly used in the art can be used, for example, water, ethanol, polyethylene glycol, 1,3-propylene glycol, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol fatty acid esters, etc.In addition, in order to prepare isotonic injections, an appropriate amount of sodium chloride, glucose or glycerol can be added to the injection preparation. In addition, conventional cosolvents, buffers, pH adjusters, etc. can also be added. In addition, if necessary, colorants, preservatives, spices, flavoring agents, sweeteners or other materials can also be added to the pharmaceutical preparation. The above dosage forms can be administered by injection, including subcutaneous injection, intravenous injection, intramuscular injection and intracavitary injection, etc.; cavity administration, such as rectal and vaginal; respiratory tract administration, such as nasal cavity; mucosal administration.

[0019] The present invention studies the inhibitory effect of oleanolic acid on pseudorabies virus in PK-15 cells and finds that oleanolic acid inhibits the expression of pseudorabies virus gD protein in a dose-dependent manner. Oleanolic acid almost completely inhibits pseudorabies virus gD protein at a concentration of 30 uM, so oleanolic acid can be used as a candidate drug for the prevention and treatment of pseudorabies virus infection.

[0020] The invention has application value in treating pseudorabies virus infection. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 The effect of different concentrations of oleanolic acid on cell viability;

[0022] Figure 2 This is the luminescence result of pseudorabies virus at different oleanolic acid concentrations;

[0023] Figure 3 This is the result of oleanolic acid inhibiting the DNA copy number of pseudorabies virus;

[0024] Figure 4 This is the result of oleanolic acid inhibiting the expression of pseudorabies virus gD protein. DETAILED DESCRIPTION

[0025] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.

[0026] The experimental methods in the following examples are conventional methods unless otherwise specified. The materials and reagents used in the following examples are conventional biochemical reagents and can be obtained from commercial sources unless otherwise specified.

[0027] Example 1. Effects of different concentrations of oleanolic acid on the viability of PK-15 cells.

[0028] In order to determine whether oleanolic acid has an effect on cell activity, the cytotoxicity of oleanolic acid was detected by CCK-8 method. PK-15 cells were plated in 96-well plates at 5000 cells / well and cultured in a 37°C, 5% CO2 incubator until they were completely attached. Oleanolic acid was gradiently diluted to 100μM, 50μM, 25μM, 12.5μM, and 6.25μM in DMEM maintenance medium with 5% FBS and added to each well, with 5 replicates for each concentration. At the same time, a negative control group and a blank group without compounds were set up, and the cells were cultured in a 37°C, 5% CO2 incubator for 24h. After 24h, new culture medium was replaced, 10uCCK-8 reagent was added to each well, and the OD value at a wavelength of 450nm was measured with an enzyme marker after incubation at 37°C for 2h. The OD values ​​under different concentration gradients were recorded, and the inhibition rate of the compound on cell viability was calculated by comparing with the blank control and positive control groups. Cell Viability % = (OD value of experimental well - OD value of blank well) / (OD value of control well - OD value of blank well) × 100%. Figure 1 As shown, the calculated half toxic concentration (CC50) was 47.17 μM.

[0029] Example 2: Oleanolic acid inhibits the replication of pseudorabies virus in PK-15 cells.

[0030] This example studies the effect of oleanolic acid on the replication of pseudorabies virus in porcine kidney cells PK-15. PK-15 cells were cultured at 3×10 5 Cells / well were inoculated in a 6-well cell culture plate, and DMEM medium containing 5% fetal bovine serum (FBS) was added. 1% penicillin and streptomycin were added to the medium, and the cells were cultured in a humidified incubator at 37°C and 5% CO2. When the cells grew to a confluence of 70%-80%, the cells were infected with the fluorescent Bartha-K61 strain of pseudorabies virus at a multiplicity of infection (MOI) of 0.1 for 1 hour. After the infection, the cells were washed three times with PBS, and the DMEM medium containing 2% FBS at concentrations of 0, 10, 20, and 30 μM oleanolic acid was replaced. After culturing for 24 hours, the virus luminescence was observed under a fluorescence microscope, and then the supernatant was collected. The supernatant DNA was extracted using TIANGEN's viral genomic DNA / RNA extraction kit according to the instructions, and then the pseudorabies virus load was detected using TIANGEN's Talent fluorescent quantitative detection kit. The results of oleanolic acid inhibiting the replication of pseudorabies virus are shown in the following figure. Figure 2 and 3 As shown, it inhibits viral replication in a dose-dependent manner, and its half inhibitory concentration (IC50) is calculated to be 10.44 μM, which can become an anti-pseudorabies virus drug.

[0031] Example 3: Oleanolic acid inhibits the expression of pseudorabies virus gD protein.

[0032] The inhibitory effect of oleanolic acid on gD protein was detected by protein immunoblotting (Western blot). Pseudorabies virus was used to infect pk-15 cells at MOI = 0.1 for 1 hour. After the infection, the cells were washed with PBS three times, and then replaced with DMEM culture medium containing 2% FBS at concentrations of 0, 10, 20, and 30 μM oleanolic acid. The cells were collected after culturing for 24 hours. The collected cell pellet was added with RI PA lysis buffer containing the protease inhibitor PMSF and lysed on ice for 1 hour, and then centrifuged at 4°C and 12000 rpm for 30 minutes to collect the protein. The protein concentration in the cell lysate was measured by the bicinchoninic acid (BCA) protein assay. Subsequently, the inhibitory effect of oleanolic acid on the gD protein of pseudorabies virus was detected by Western blot, and the results are shown in Figure 2. Figure 3 As shown, similar to the results of inhibiting viral replication, oleanolic acid inhibited the expression of pseudorabies virus gD protein in a dose-dependent manner. Oleanolic acid completely inhibited pseudorabies virus gD protein at a concentration of 30uM, demonstrating that oleanolic acid has good anti-pseudorabies virus activity.

[0033] The above study on the inhibitory effect of oleanolic acid on pseudorabies virus in PK-15 cells shows that oleanolic acid can be used as a preventive and therapeutic drug for pseudorabies virus infection. The present invention has application value in the treatment of pseudorabies virus infection.

[0034] The present invention has been described in detail above. For those skilled in the art, without departing from the purpose and scope of the present invention, and without the need to carry out unnecessary experimental conditions, the present invention can be implemented in a wide range under equivalent parameters, concentrations and conditions. Although the present invention provides specific embodiments, it should be understood that the present invention can be further improved. In a word, according to the principles of the present invention, the application is intended to include any changes, uses or improvements to the present invention, including departure from the disclosed scope in the application, and changes made with conventional techniques known in the art.

Claims

1. Use of oleanolic acid in the preparation of a drug for preventing and / or treating a disease caused by pseudorabies virus or a drug for pseudorabies virus infection; the structural formula of the oleanolic acid is:

2. The use according to claim 1, characterized in that: The drug is administered to a mammal.

3. Application of oleanolic acid in the preparation of pseudorabies virus inhibitors.

4. The use according to claim 3, characterized in that: The inhibitor is administered to a mammal.

5. Application of oleanolic acid in the preparation of drugs for inhibiting the proliferation of pseudorabies virus.

6. The use according to claim 5, characterized in that: The drug is administered to a mammal.

7. Use of oleanolic acid in the preparation of drugs for inhibiting the cytopathic effect of pseudorabies virus.

8. The use according to claim 7, characterized in that: The cells are mammalian cells.

9. The use according to claim 8, characterized in that: The mammalian cells are pig cells.

10. A pseudorabies virus inhibitor, characterized in that: The active ingredient of the pseudorabies virus inhibitor contains oleanolic acid.